NCT00918814已完成2 期
A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 54
- 主要终点
- Safety: physical examinations, laboratory tests, AE assessment
研究概览
简要总结
Dose Ranging and Dose Frequency of LIPO-102
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or non pregnant female
- •Good general health
- •Sufficient abdominal fat for injections
- •Signed informed consent
排除标准
- •Known hypersensitivity to study drugs
- •Treatment with an investigational agent within 30 days of first dose
研究组 & 干预措施
LIPO-102
Experimental
LIPO-102
干预措施: LIPO-102 (Drug)
Placebo
Experimental
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Safety: physical examinations, laboratory tests, AE assessment
时间窗: 4 weeks treatment and 4 weeks follow up
次要结局
- Efficacy: change in subcutaneous abdominal adipose tissue thickness(4 weeks treatment and 4 weeks follow up)
研究者
相似试验
已完成
1 期
Levodopa Concentration Profile With Stalevo 75/125 mgParkinson's DiseaseNCT01070628Orion Corporation, Orion Pharma20
已完成
2 期
Dose Ranging StudyPeriumbilical Subcutaneous Adipose Tissue ReductionNCT01802723Neothetics, Inc472
已完成
1 期
An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy VolunteersSubcutaneous Adipose Tissue ReductionNCT00918606Neothetics, Inc30
已完成
2 期
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular DegenerationMacular DegenerationNCT01134055GlaxoSmithKline510
已完成
2 期
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary InsomniaPrimary InsomniaNCT00551148Pfizer92